CHOLINE C-11
Peakcholine c-11
NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
CHOLINE C-11 (choline c-11) is radiopharmaceutical activity [moa]. Approved for prostate cancer. First approved in 2012.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLINE C-11 is a radioactive diagnostic agent administered intravenously for positron emission tomography (PET) imaging of prostate cancer. It works as a radiopharmaceutical that localizes to prostate tissue, enabling detection and staging of malignant disease. The product leverages carbon-11 radiolabeling to provide real-time metabolic imaging.
Peak
CHOLINE C-11 is at peak commercial maturity with established market presence, suggesting stable but not rapidly expanding team sizes in commercial and medical affairs.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Career Relevance
Working on CHOLINE C-11 positions you in a stable, mature diagnostic franchise with limited growth headroom but strong clinical integration opportunities in urology and oncology. Career development here emphasizes deepening clinical relationships, optimizing market penetration, and defending market share against superior imaging modalities.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.